Name of the Procedure:

Injection, sacituzumab govitecan-hziy, 2.5 mg
Common name: Sacituzumab Govitecan Injection
Medical term: J9317 Administration

Summary

This procedure involves administering sacituzumab govitecan, a medication used in cancer treatment, through an injection. The medication is delivered directly into the bloodstream to help manage certain types of cancer, providing targeted therapy aimed at combating the disease.

Purpose

• Medical Conditions: Primarily used for the treatment of certain types of metastatic breast cancer, especially when other treatments have not been effective.
• Goals: To slow down or stop the growth of cancer cells, reduce tumor size, and improve survival rates.

Indications

• Symptoms: Primarily indicated for patients with metastatic breast cancer who have received at least two prior treatments.
• Patient Criteria: Suitable for adult patients with advanced cancer stages that are not responding to conventional therapies.

Preparation

• Pre-procedure Instructions: Patients may need to fast for a few hours prior to the injection, depending on specific medical advice.
• Diagnostic Tests: Blood tests and imaging studies (CT, MRI) might be required to evaluate the patient's current health status and cancer progression.

Procedure Description

1. Pre-treatment Assessment: Vital signs checked, and a physical exam conducted.
2. Administration: The injection is usually given intravenously (IV). The healthcare provider will insert a needle into a vein, commonly in the arm.
3. Monitoring: The patient will be monitored for any immediate side effects during and after the administration.

• Tools/Equipment: IV needle, syringes, and monitoring equipment.
• Anesthesia/Sedation: Not typically required for this injection.

Duration

• Procedure Time: The injection itself takes around 30 to 60 minutes. Additional monitoring may extend the total visit time to a few hours.

Setting

• Location: Usually performed in a hospital's outpatient clinic or a dedicated cancer treatment center.

Personnel

• Healthcare Professionals: Oncologist, nurse, and potentially a pharmacist.

Risks and Complications

• Common Risks: Nausea, fatigue, hair loss, decreased blood cell counts.
• Rare Risks: Severe allergic reactions, severe neutropenia, and higher risk of infection.
• Management: Immediate medical support for allergic reactions or infections; hospital admission if necessary.

Benefits

• Expected Benefits: Potential tumor shrinkage, slowed cancer progression, and extended survival rate. Benefits usually begin to appear after several weeks of treatment.

Recovery

• Post-procedure Care: Regular monitoring of blood counts, managing side effects with supportive care, and following up with the oncologist.
• Recovery Time: Continuous treatment cycles with breaks in between; specific timeframe varies per individual based on response and tolerance.

Alternatives

• Other Treatments: Hormonal therapies, other chemotherapeutic agents, immunotherapy, radiation therapy.
• Pros and Cons: Alternatives may have different efficacy rates and side effect profiles; sacituzumab govitecan is often chosen after other options have failed.

Patient Experience

• During Procedure: Mild discomfort from the IV insertion; usually no significant pain.
• After Procedure: Possible tiredness, need for rest, side effects like nausea managed with medications, and continuous assessment and support for any arising issues.

Pain management includes prescribed medications if needed and supportive care measures to maintain comfort and quality of life.